New Drug Combination is the Next Best Treatment for Ovarian Cancer Patients
According to an interim result, a targeted drug combination could prove two times more effective on ovarian cancer patients. In this episode, we will talk about the new drug combination.
But first, please like the video and subscribe to our channel for more such content in the future. Push the bell icon to receive updates every time we upload a video.
Researchers and scientists are hopeful that the new targeted drug combination will provide a new option for patients suffering from advanced low-grade serous ovarian cancer (LGSOC)—a type of cancer that has a poor response rate to current drugs.
Researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, studied the effects of avutometinib in combination with defactinib. Researchers also studied avutometinib when administered without the combination in twenty-nine patients suffering from LGSOC. Both drugs are effective in blocking signals that allow cancer cell growth.
An article published on the official website of The Institute of Cancer Research mentions the following:
“According to these results, nearly half (45 percent) of patients treated with autometinib in combination with defactinib saw their tumors shrink significantly, suggesting the new combination could be almost twice as effective as the next best treatment.
Responses to the drug combination were particularly promising in those with a mutation in a gene called KRAS, with six in 10 (60 percent) patients experiencing significant tumor shrinkage. However, nearly a third (29 percent) of patients without the mutation also had an encouraging response, which is also an improvement on standard treatment.”
Avutometinib is a targeted drug that blocks proteins encouraging cancer cell growth; however, the drug becomes ineffective as tumors become resistant to treatment over time. Researchers found that when the drug was combined with defactinib, the treatment became four times more effective.
Dr. Susana Banerjee, global lead investigator of the study, said, “These initial results could be fantastic news for women with low-grade serous ovarian cancer, indicating a far more effective option than current treatments may be on the horizon.
“It’s wonderful to see so many patients experience a meaningful response to this innovative drug combination and I’m so grateful to all who joined the trial, making this research possible. Low-grade serous ovarian cancer does not respond well to currently approved treatments, so these results could represent a significant breakthrough in treating the disease,” she further added.
How did you find this information? Please mention this in the comments section. We would also like to know the kind of content you want to watch, and we will try to create it for you. For more news and updates, follow Airr News.
#OverianCancer #Cancer #CancerCells #Immunotherapy #Chemotherapy #Cancerfree #Tumor #Surgery #RadiationTherapy #Health #Wellness #ClinicalTrial #MiracleDrug #ImuunotherapyDrug #DrugCombination #combination #overian #proteins #KRAS #india #airrnews
